Jack Schalken, PhD

Schalken, Jack 2019 120x160Jack A Schalken PhD (1959) has an appointment as professor of experimental urology at Radboud University MC, Nijmegen. Dr Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was (co) appointed as professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).

His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes.

Dr Schalken is member of 12 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as ESUR, SBUR, EAU, ASCO and ESMO. Dr Schalken was co-founder and CSO of NovioGendix BV, a biomarker company recently acquired by MDxHealth SA and Oncodrone BV, a biopharmaceutical company.

Dr Schalken is (co)author on more than 340 peer reviewed publications, 81 book chapters and has edited 10 books/special journal issues. He supervised 34 completed PhD theses. He is inventor on approximately 20 patent applications (some still pending approval).